Galina Vayner, MD
Internal Medicine · Norcross, GANPI 1891786497
Payments from drug & device makers
Across 150 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$834
- AbbVie$266
- Sumitomo Pharma America, Inc.$253
- Ferring Pharmaceuticals Inc.$193
- Abbott$185
- GSK$146
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $834 |
| AbbVie(2 entities) | 15 | $266 |
| Sumitomo Pharma America, Inc. | 10 | $253 |
| Ferring Pharmaceuticals Inc. | 12 | $193 |
| Abbott | 5 | $185 |
| GSK | 9 | $146 |
| Exact Sciences | 6 | $101 |
| AstraZeneca | 6 | $96 |
| Corium, LLC | 4 | $93 |
| Amgen | 5 | $80 |
| Amarin Pharma, Inc. | 5 | $73 |
| Pfizer | 3 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $47 |
| Baxter Healthcare | 1 | $44 |
| Johnson & Johnson | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Ardelyx, Inc. | 1 | $27 |
| Teleflex LLC | 1 | $25 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Biogen | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$105
How this compares
$2,914 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 489 | $554,805 |
| LinzessLinaclotide | 525 | $496,088 |
| OzempicSemaglutide | 341 | $384,658 |
| RybelsusSemaglutide | 203 | $327,178 |
| EliquisApixaban | 300 | $300,198 |
| Metformin Er GastricMetformin Hcl | 77 | $267,371 |
| XareltoRivaroxaban | 203 | $211,622 |
| JanuviaSitagliptin Phosphate | 164 | $179,918 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 234 | $168,417 |
| JardianceEmpagliflozin | 127 | $148,839 |
| CreonLipase/Protease/Amylase | 140 | $133,667 |
| Tresiba Flextouch U-100Insulin Degludec | 208 | $129,144 |
| ProliaDenosumab | 74 | $127,228 |
| MyrbetriqMirabegron | 144 | $123,672 |
| GemtesaVibegron | 91 | $84,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $834 | $711,836544 claims |
| AbbVieLinzess, Creon, Restasis | $266 | $652,653689 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $96 | $632,583613 claims |
| PfizerEliquis | $66 | $300,198300 claims |
| Johnson & JohnsonXarelto | $44 | $211,622203 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $146 | $203,694302 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $47 | $182,552171 claims |
| AmgenProlia | $80 | $127,22874 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $123,672144 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $253 | $84,12191 claims |
| Aimmune Therapeutics, Inc.Zenpep | $16 | $81,26447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Norcross
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.